TIL therapy development focuses on isolating and expanding tumor-infiltrating lymphocytes from patient tumors to enhance antitumor immunity. This approach supports personalized immunotherapy for solid tumors, integrating rapid expansion protocols, neoantigen targeting, and genetic engineering to improve cytotoxicity, overcome immunosuppression, and boost therapeutic outcomes
